Sagimet Biosciences announces positive topline results from phase 2b trial of denifanstat
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Marks the World Head & Neck Cancer Day at the OCTF Conference
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
The only definitive way to diagnose and stage lung cancers is through biopsies
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Subscribe To Our Newsletter & Stay Updated